Własność intelektualna i biotechnologia oraz nowe leki

• Authors: Aleksandra Twardowska

Title variants

EN

Intelectual property rights, biotechnology and innovative medicines

• Languages of publication: PL EN

Abstracts

EN

Intellectual property rights (IPR) are the main requirement of the implementation of inventions. The IPR system in Central Europe (CE) has some specificity in comparison to the "old EU 15". The key contribution of the research-based pharmaceutical industry to medical progress is to turn fundamental research findings into innovative and commonly accessible treatments. The creation of an innovative medicine requires a strong research organization and accumulation of enormous financial resources. Counterparts of innovative medicines the protection of which has expired are generic medicines. All of the CE states now offer product patents, but the IPR regulations were introduced in the early 1990s. One of the most important issues for pharmaceutics in the EU expansion concerns intellectual property protection.

• Journal: Kosmos
• Year: 2007
• Volume: 56
• Issue: 3-4
• Pages: 227-232

Dates

published

2007

Contributors

author

Aleksandra Twardowska

• Biuro Patentów i Znaków Towarowych Jan Wierzchon & Partnerzy, Żurawia 47/49, 00-680 Warszawa, Polska

References

• USTAWA z dn. 30 czerwca 2000. Prawo własności przemysłowej. Dz. U. 119 poz. 1117, z późn. Zmianami.
• Filipiak K., 2002. Leki oryginalne a generyczne. Meritum 3, Okręgowa Rada Lekarska w Toruniu.
• Grzesiczak M., 2005. Koszty procedury zgłoszeniowej w trybie PCT. Nowator 21, 12-13.
• Kaliszan R., Janicki S., 2001. Biorównoważ ność leków. Farm. Pol. 57, 456-462.